OncoMatch/Clinical Trials/NCT05652686
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Is NCT05652686 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments for small cell lung cancer (sclc).
Treatment: Peluntamig (PT217) · Carboplatin + Etoposide · Paclitaxel. · Atezolizumab · Lurbinectedin · Irinotecan (drug) · Topotecan — This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Small Cell Lung Cancer
Neuroendocrine Tumor
Pancreatic Cancer
Biomarker criteria
Required: DLL3 expression (testing required; no eligibility threshold specified)
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG performance status of 0 or 1
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) · Duarte, California
- Sarah Cannon Research Institute at HealthONE · Denver, Colorado
- Sidney Kimmel Comprehensive Cancer Center at John Hopkins · Baltimore, Maryland
- Massachusetts General Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05652686 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require DLL3?
Yes, DLL3 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify